Combination therapies delay cognitive decline over 10 years in Alzheimer’s NACC participants

Abstract

AbstractINTRODUCTIONDelaying cognitive decline in Alzheimer’s disease can significantly impact both function and quality of life.METHODSLongitudinal analysis of National Alzheimer’s Coordinating Center (NACC) dataset of 7,653 mild dementia CDR-SB AD participants at baseline with prescriptions for diabetes (DBMD), lipid-lowering (LIPL), anti-hypertensive (AHTN), and non-steroidal anti-inflammatory (NSD) medications over 10 years was evaluated for change in cognitive function relative to non-treated stratified by sex and APOE genotype.RESULTSCombination therapy of DBMD+LIPL+AHTN+NSD resulted in a 44% / 35% (MMSE/CDR-SB) delay in cognitive decline at 5 years and 47% / 35% (MMSE/CDR-SB) delay at 10 years. Females and APOE4 carriers exhibited greatest cognitive benefit of combination therapy.DISCUSSIONCombination therapies significantly delayed cognitive decline in NACC AD participants at a magnitude comparable to or greater than beta-amyloid immunomodulator interventions. These data support combination precision medicine targeting AD risk factors to alter the course of the disease that persists for a decade.